echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 6 target research and development hot 5 more than 1 billion varieties have been born Who will be "antibody king"?

    6 target research and development hot 5 more than 1 billion varieties have been born Who will be "antibody king"?

    • Last Update: 2020-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At present, there are more than 150 enterprises in China layout of 311 antibody drugs, including VEGF, HER2, TNF alpha, PD-1/PD-L1, EGFR, CD20 six targets developed the most hot, then these targets of the representative drugs? How's research and development going in China?the global "drug king" busy price reduction, the first biosimilar drug has been listed
    November 7, the State Drug Administration issued a letter, Baioti developed adamu mono-anti-injection (commodity name Greeli) listing registration application has been approved recently, becoming the first approved Adamu mono-anti-biosimilar drug, used to treat strong spinal inflammation, rheumatoid arthritis and psymfort disease and other autoimmune diseasesAccording to Minenet data, AbbVie developed the Adamu mono-resistance (commodity name Sumeile) since 2012 to win the title of "global drug king", in 2013 global sales exceeded 10 billion U.Sdollars for the first time, the first half of 2019 reached 9.32 billion U.SdollarsAlthough Adamu single resistance in the global market has repeatedly created a sales miracle, but in the Chinese market sales is not depressed, in 2018 in China's public medical institutions terminal sales of only 87.15 million yuan, which may be related to ShumeiLe in the domestic approval of less indications and by similar competition, as well as not into the national health insurance expensive, drug access is not highTable 1: ShuMeile recently in some provinces and cities of the price reduction (unit: Yuan / branch)(source: provincial and municipal recruitment platform)in May 2019, Shumeile unexpectedly participated in price competition, in Jiangxi Province, the price adjustment to 3160 yuan / branch, a decrease of nearly 60%, and then in Beijing, Shaanxi, Jiangsu, Gansu, Yunnan, Liaoning and other provinces and cities to take the initiative to reduce pricesThe reason is, one is to "stitch in" medical insurance preparation, 2019 health insurance negotiations have been carried out, according to industry news, Adamu single resistance has been successfully entered into health insurance, which will improve the sales of Shumel will be of great help;Baiote's Adamu mono-anti-biosimilar drug has been successfully approved for the market, in the face of TheumeiLe's initiative to reduce prices, or will bring some pressure on its pricingWith more and more biosimilar drugs approved for market, the future of Adamu mono-resistance drug accessibility will be greatly improved, whether to become "China's new era of drug king", we wait and see!domestic scale has exceeded 16 billion yuan, focusing on 3 treatment areas
    According to Mi net statistics, the current domestic market approved import / approved listed antibody drugs (including fusion protein, the same below) has more than 40 (in the name of drugs plus enterprises), of which 14 domestic single resistance, import single resistance 28, in 2018 in China's public medical institutions terminal sales total sales scale of more than 16 billion yuanZhang Buyong, general manager/chief researcher of Minet, recently predicted at the 2019 National Pharmaceutical Economic Information Conference that the scale of sales of antibody drugs is expected to reach 50 billion to 55 billion yuan in the next five yearsthe antibody drugs currently on the market cover therapeutic areas such as anti-tumor, autoimmune diseases, musculoskeletal systems, sensory systems, etcAnti-tumor drugs and autoimmune diseases accounted for more than 30 varieties, far ahead, followed by ophthalmology drugs, there are 3 drugs belong to the field of treatment, it can be seen that antibody drugs in the anti-tumor, autoimmune diseases, ophthalmology in the three areas of application is more extensiveTable 2: 2018 China's public medical institutions terminal sales of 100 million antibody drugsNote: after the end of 2018 approved(source: RiceNet database)2018 China's public medical institutions terminal sales of 12 billion antibody drugs (" In the name of drugs), 8 of them are anti-tumor drugs, 2 are autoimmune disease drugs, these 10 drugs in 2018 total sales of more than 12 billion yuan;from the sales situation, the import of antibody drugs, Roche "troika" performance bright, in 2018 in China's public medical institutions terminal sales are more than 2 billion yuan; The only domestic antibody drugs that have broken through 1 billion yuan, however, this pattern is expected to be broken soon, according to the announcement of listed companies, Junshi, Cinda PD-1 in the first half of 2019 to achieve 308 million yuan, 332 million yuan of sales, is expected to exceed the sales scale of 1 billion yuan in the first year of listingfrom the drug treatment target point, 12 antibody drugs cover VEGF, TNF alpha, PD-1, EGFR, HER2, CD20 and other treatment targets, and these targets are currently the domestic research and development of hot targets6 targets research and development "hot", biological drugs will be outbreakFigure 1: antibody drugs different research and development targets accounted for(source: Minet Global New Drug Research and Development Monitoring Database)as of September 2019, a total of more than 150 enterprises in China laid out 311 antibody drugs, of which VEGF as the target of 47 Varieties, with PD-1/PD-L1 as the target of 44 varieties, TNF alpha as the target of 34 varieties, HER2 as the target of 30 varieties, EGFR, CD20 as the target of 23 varieties, the six targets of the most popular research and developmentZhang said that in the next two years, there will be 10-15 antibody drugs approved for the marketFigure 2: Domestic declaration of antibody drug varieties more than 5 enterprises(source: rice net database)from the antibody drug declaration enterprises, there are currently Hengrui Pharmaceuticals, Cinda Bio, Qilu Pharmaceutical, Fuhong Hanxuan, Haizheng Pharmaceutical son 16 enterprises declared more than 5 varietiesdomestic has been listed to VEGF as the target of antibody drugs have beva pearl monoantigen, thunder ball monoantigen, Aberxip and so on The research and development of bevalpearl mono-biosimilar drug is the hottest, at present Qilu, Cinda's products have applied for listing, of which Qilu's fastest progress, is expected to win the first Bevalazhu mono-biosimilar drug In addition, Zhengda Tianqing, Hengrui Pharmaceuticals, Fuhong Hanxuan and other more than 10 enterprises are carried out to Phase III clinical trials, in the first echelon of development domestic has been listed with TNF alpha as the target of antibody drugs such as Adamu monoantigen, invrixixim and so on The first Adamu mono-anti-biosimilar drug has been approved for listing, flowering Bai otai, in addition to Haizheng, Cinda, Fuhong Hanxuan, Junshi four enterprises have submitted a listing application, Zhengda Tianqing, Shenzhou cell engineering, Tonghua Dongbao and other enterprises' products have been carried out to Phase III clinical trials; domestic has been listed in HER2 as the target of antibody drugs have qutobeu monoantigen, patobezumab and so on Sansheng Guojian, Fuhong Hanxuan has submitted quto Zhu single anti-biosimilar drug listing application, of which Sansheng Guojian progress edgy faster, in addition to Jiahe Biological, Zhengda Tianqing, Anke Biological and other enterprises in the third phase of clinical domestic lyse-targeted antibody drugs with CD20 as a target are beneficial totoxire The first rituxima monobiotic similar ity drug has been approved for listing, flowering the hong Hanxuan, in addition to Cinda's products have been submitted to the listing application, Shenzhou Cell Engineering, Hualan Gene, Xikang Bio, Zhengda Tianqing, Haizheng Pharmaceuticals and other enterprises in the clinical phase III domestic has been listed in The EGFR as the target of antibody drugs have situsione monoantigen, nitozumab and so on Taizhou Maibo Tei Pharmaceuticals' Sitoshi mono-biosimilar situ in clinical phase III, Qilu Pharmaceuticals, Sansheng Guojian, Jingze Bio and other enterprises' products are in clinical Phase I domestic antibody drugs that have been listed to PD-1 targets have Navoliu monoantigen, Paboli zhu mono antigen, Trepri monoantigen, Sindili mono-resistance, Carrie-Zun mono-resistance, of which the last 3 are domestic PD-1, Baiji Shenzhou BGB-A317 has submitted a listing application, in the clinical phase III PD-1 has the hlXX10 Domestic has not yet PD-L1 as a target of antibody drugs approved for listing, the world has been approved three PD-L1 has been approved for listing, respectively, Roche's atezolizumab (atlizumab), AstraZeneca's durvalumab (Duvalu monoantigen), Merck's avelumab (Aviru mono resistance), Atlizhu mono- anti-resistance, Duvalu mono-resistance has been in the domestic review stage Among domestic pharmaceutical companies, PD-L1 in clinical phase III has Corning Jerry/Think-Di KN035, Keystone Pharmaceuticals' CS1001, Hengrui Pharmaceuticals' SHR-1316, TQB2450, and so on At present, some domestic enterprises have independently developed PD-1/PD-L1 to the international market, Hengrui, Corning Jerry, Baiji Shenzhou, Fuhong Hanxuan, Lizhu single resistance, Junshi, etc have submitted new drug clinical trials to the FDA the original title: 6 target research and development hot, 5 more than 1 billion varieties have been born, Hengrui, Fosun, Cinda .. Who is the "Antibody King"? source: Internet database Note: data statistics as of November 11, if there are omissions, welcome to refer to positive
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.